The mechanism by which patients with portal hypertension develop portal hypertensive ... of the free or wedged hepatic vein in hepatic cirrhosis. [22] Various studies have shown that the ...

The most common cause of portal hypertension is cirrhosis of the liver, which is scarring that accompanies the healing of liver injury caused by hepatitis, alcohol, or other less common causes of ...

Treatment for portal hypertension in patients with cirrhosis is based on the use of β-blockers with or without organic nitrates; however, these agents are effective in less than 50% of patients ...

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the ...

They develop in approximately 50% of people with portal hypertension, a severe complication of cirrhosis (liver scarring).

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...

Forty-six patients, 32 males and 14 females with portal hypertension and cirrhosis, were evaluated. The mean age of these patients was 48 ± 12 years (mean ± SD). In 43.5% of cases, cirrhosis ...